相关实验视频
Updated: Sep 15, 2025

12:24
Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes
Published on: June 3, 2014
12.4K
因子IXa和因子X影响因子VIIIa的稳定性和失活机制在体外和体外
Johnathan J Morris1, Nicole A Parsons1, Amelia R Wilhelm2
1Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States.
Blood
|July 15, 2025
概括
了解八因子 (FVIII) 如何失活是治疗血友病A的关键. 这项研究表明,与FIXa和FX的相互作用,以及A2域解离和APC裂变,调节FVIIIa活动,并可以改善治疗.
科学领域:
- 生物化学 生物化学
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
背景情况:
- 第八因子 (FVIII) 缺乏会导致血友病A,而过多的FVIII活性会增加血栓形成的风险.
- 了解FVIII无活化机制对于疾病病理学和治疗开发至关重要.
- 已确定的FVIIIa无活化途径包括A2域解离和活性蛋白C (APC) 蛋白解.
研究的目的:
- 研究FVIIIa与FIXa和FX的结合相互作用对FVIIIa无活化的体内影响.
- 阐明A2域解离和APC裂变在FVIIIa调节中的作用.
- 评估调节FVIIIa无活化机制的治疗潜力.
主要方法:
- 利用复合FVIIIa变异来研究A2域解离和APC裂变.
- 采用生物化学分析和血友病A (HA) 鼠标损伤模型.
- 在体内分析了FVIIIa无活化和静血功能.
主要成果:
- 结合FVIIIa的FIXa稳定了A2域,增强了APC介导的失活.
- 在体内,FIXa和FX部分保护FVIIIa免受APC在特定部位的裂变.
- FVIIIa的APC无活化比FVIII的APC无活化更为显著.
- 稳定A2域或抑制APC裂变改善了小鼠中的FVIII功效.
结论:
- 无论是A2域解离还是APC裂变,都对体内FVIIIa调节至关重要.
- FIXa相互作用影响FVIIIa无活化通路.
- 调节FVIIIa无活化机制为提高FVIII治疗疗效提供了一个有希望的策略.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
917
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
917
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Extrinsic and Intrinsic Pathways of Hemostasis
9.3K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
9.3K
Factors Affecting Protein-Drug Binding: Protein-Related Factors
264
Drug binding to proteins is a key aspect of pharmacokinetics and can influence a drug's distribution, absorption, and elimination in the body. Several factors, including the drug's physiochemical properties, protein concentration, disease states, and the number of binding sites on the protein, influence this process.
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
264
Factors Affecting Protein-Drug Binding: Drug-Related Factors
206
Drug binding to proteins is a complex phenomenon influenced by various drug-related factors, each playing a significant role in the interaction between drugs and proteins within the body.
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
206
Factors Affecting Drug Biotransformation: Biological
244
Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...
244

